New Study Raises Concerns About GLP-1 Weight Loss Medications and Brain Health
Recent research from the University of California San Diego highlights potential health risks associated with popular weight-loss medications known as GLP-1 receptor agonists. These medications, including semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound), may be linked to a rare but serious brain condition called Wernicke encephalopathy.
Wernicke encephalopathy is caused by a severe deficiency of vitamin B1 and can lead to dangerous neurological problems. In their study published in Clinical Nutrition, researchers reported 15 cases where individuals taking GLP-1 medications developed this disorder. Most of these patients experienced gastrointestinal symptoms such as weight loss and loss of appetite, which could contribute to nutritional deficiencies.
According to the findings, these cases appeared more frequently among users of GLP-1 medications compared to those on other types of drugs. However, the researchers caution that their study does not definitively prove the medications caused the brain condition.
Vitamin B1 is crucial for brain function, and its deficiency can lead to confusion, difficulty walking, balance issues, and vision changes. If not treated promptly, it can result in permanent neurological damage or even death.
Karthik Achari, a clinician from Chicago and founder of PepMD, emphasizes that while the cases are concerning, they are quite rare. “Finding 15 cases in a large population using these drugs shows this issue is uncommon,” he explained. However, he acknowledged the seriousness of the condition.
GLP-1 medications work by reducing appetite, which can lead some people to eat less food, potentially causing a decrease in their intake of essential nutrients like vitamin B1. Achari urges caution for individuals who have ongoing nausea and vomiting, experience rapid weight loss, have undergone bariatric surgery, or consume alcohol heavily, as they may be at higher risk for developing this deficiency.
Nutritionist Erin Palinski-Wade also stresses the importance of maintaining a balanced diet while on a GLP-1 medication. She points out that the appetite-suppressing effects of these drugs can result in unintentional under-eating of critical nutrients, such as protein, fiber, and fluids. “Patients should not overlook persistent symptoms like vomiting or diarrhea, as these can lead to dehydration and kidney issues,” she advised.
The researchers behind the study have acknowledged that their findings are based largely on adverse event reports and do not establish a direct cause-and-effect relationship. They are calling for more extensive research to further explore this potential health risk. In the meantime, patients taking GLP-1 medications are advised not to halt their use based solely on these findings without consulting their healthcare provider.
As this study suggests both the benefits and potential risks linked to GLP-1 medications, ongoing attention and research are essential to ensure patient safety.
